Skip to main content
TipRanks
Go Ultimate75% OFF

Careium AB (CARE) AI Stock Analysis

1 Followers
SE:CARE

Careium AB

(Nasdaq OMX AB:CARE)

Select Model
Rating:68Neutral
Price Target:SEK 32.00â–²(5.61% Upside)
Action:reiterated
Date:10/24/26

Careium's overall score of 68 reflects a fundamentally sound company with a strong balance sheet and improving cash flows, which are the most significant positive factors. The stock's technical trend is healthy, trading above key moving averages with neutral momentum. Valuation is fair but unremarkable, with a moderate P/E and no dividend. The primary risk is the recent contraction in free cash flow growth and EBIT margins that have not fully recovered to prior highs, which tempers the score from being higher.

Positive Factors
Revenue RecoveryThe return to revenue growth indicates renewed demand and improving commercial execution after the prior dip. Sustained expansion would increase the installed base supporting service revenue, improve operating leverage, and strengthen Careium’s ability to reinvest in its telecare platform.
Negative Factors
Modest ProfitabilityAlthough profitability has rebounded, a roughly 4% net margin leaves limited room for cost increases or execution setbacks. The decline from stronger 2024 margins suggests operating leverage remains constrained, which may limit earnings growth even if revenue continues expanding.

Careium AB (CARE) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%SE:CARE+14.77%EWD+11.97%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 737.08M
Dividend Yield
―
Average Volume (3M)
16.09K
Price to Earnings (P/E)
14.9
Beta (1Y)
0.36
Revenue Growth
12.86%
EPS Growth
18.01%
Country
Sweden
Employees
613
Sector
General
Sector Strength
55
Industry
Security & Protection Services

Careium AB Business Overview & Revenue Model

Company Description

Careium AB (Publ), established in 1974 and headquartered in Malmö, Sweden, specializes in providing technologically advanced care solutions across numerous European nations, including Sweden, Norway, the United Kingdom, and the Netherlands. Their ext...

How the Company Makes Money

Careium makes money by selling and supporting telecare offerings that combine hardware and ongoing service delivery. Revenue is typically generated through: (1) service fees for operating telecare solutions, which can include hosting/operating the pl...

Careium AB Financial Statement Overview

Summary

Careium's financial health is solid, driven by a strong balance sheet with low leverage (debt-to-equity 0.29) and robust cash flow generation. The income statement shows a successful growth turnaround with TTM revenue up 5% and expanding EBITDA margins, though operating profitability has yet to reclaim prior peaks. Overall, the company demonstrates good operational leverage and a commitment to deleveraging.

Income Statement

68Positive

Balance Sheet

78Positive

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue961.70M854.10M870.70M824.60M725.10M587.50M
Gross Profit419.40M375.10M373.70M340.50M273.70M240.30M
EBITDA142.30M120.60M150.60M137.90M67.90M65.10M
Net Income50.60M35.80M58.40M37.90M-8.60M4.70M
Balance Sheet
Total Assets1.14B1.09B1.05B961.40M992.10M1.05B
Cash, Cash Equivalents and Short-Term Investments28.00M54.90M31.90M31.50M39.90M142.50M
Total Debt219.20M209.70M196.80M225.30M322.70M292.30M
Total Liabilities424.70M407.40M371.40M361.90M425.50M500.20M
Stockholders Equity717.70M681.50M678.20M599.50M566.60M551.50M
Cash Flow
Free Cash Flow63.50M51.30M36.90M61.90M-87.10M-70.90M
Operating Cash Flow131.90M143.40M92.90M111.90M-21.10M-19.80M
Investing Cash Flow-97.10M-102.20M-56.00M-50.00M-68.70M-163.70M
Financing Cash Flow-37.50M-13.70M-39.60M-69.70M-15.10M291.00M

Careium AB Technical Analysis

Technical Analysis SentimentPositive
Last Price30.30

Price Trends

50DMA28.08Positive
100DMA28.46Positive
200DMA25.58Positive

Market Momentum

MACD0.64Negative
RSI61.33Neutral
STOCH81.55Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARE, the sentiment is Positive. The current price of 30.30 is above the 20-day moving average (MA) of 29.31, above the 50-day MA of 28.08, and above the 200-day MA of 25.58, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 61.33 is Neutral, neither overbought nor oversold. The STOCH value of 81.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CARE.

Careium AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:CARE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:DEDISE:DEDI73OutperformSEK 684.47M13.59―2.55%9.56%20.95%
SE:CARESE:CARE68NeutralSEK 737.08M14.85――12.86%18.01%
SE:PTRKSE:PTRK59NeutralSEK 171.55M-1.95――-10.30%-11.59%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:NNHSE:NNH51NeutralSEK 96.03M20.95―1.61%2.70%-43.94%
SE:BOULSE:BOUL41NeutralSEK 47.96M-2.75-58.52%―-16.09%78.68%

* General Sector Average

Performance Comparison

0%200%400%SE:CARESE:MVIRSE:BOULSE:NNHSE:DEDISE:PTRKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:CARE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:CARECareium AB30.304.4016.99%
SE:MVIRMedivir1.120.67149.78%
SE:BOULBoule Diagnostics AB1.24-4.52-78.56%
SE:NNHNew Nordic Healthbrands AB15.50-6.34-29.04%
SE:DEDIDedicare AB68.5026.6763.76%
SE:PTRKPhysitrack Limited10.55-4.35-29.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026